PharmaléaH
ActiveThe computed 12-month bankruptcy probability of PharmaléaH is 2.6% (moderate). The 2025 annual accounts show equity of €1.06M and a net result of €383k. Equity is growing by ~15.1% per year across the filed fiscal years. Its solvency ranks better than 56% of 17987 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
Axes · tick = 2024
Profitability100▲+63
Solvency52▲+17
Growth52=
Stability94
Bankruptcy probability, 12 months
2.6%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €60k at 30 days acceptable
Liquidity short (current ratio 0.03 against 0.01 in 2024), and 58.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
41.3%
Return on assets
15%
Age of the figures
8 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-07-2026, 22 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
22 d early
2024
28 d late
2023
21 d early
2022
28 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
13-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€383k▲ 579%
2024 · €56k
2022: €622k
2023: €71k
2024: €56k
2022 → 2025
Working capital
€-378k▲ 34.9%
2024 · €-581k
2022: €-505k
2023: €-536k
2024: €-581k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€627k-€697k▲ 11.3%€754k▲ 8.1%€1.06M▲ 40.5%
Operating result€123k-€132k▲ 7.8%€101k▼ 23.8%€103k▲ 2.3%
Net result€622k-€71k▼ 88.6%€56k▼ 20.0%€383k▲ 579%
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 2% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €2.56M
Fixed assets
€2.55M=
Current assets
€11k▲ 58.9%
Equity and liabilities €2.56M
Equity
€1.06M▲ 40.5%
Debt
€1.51M▼ 16.7%
The debt ratio falls from 70.6% to 58.7%: equity grows while debt is paid down.
Key figures and ratios
Solvency
41.3%▲
2024 · 29.4%
Current ratio
0.03▲
2024 · 0.01
Quick ratio
0.03▲
2024 · 0.01
Debt / equity
1.42▼
2024 · 2.40
ROE
36.2%▲
2024 · 7.5%
ROA
15.0%▲
2024 · 2.2%
Debt
€1.51M▼
2024 · €1.81M
Debt ≤ 1 year
€389k▼
2024 · €588k
Debt > 1 year
€1.12M▼
2024 · €1.22M
Income taxes
€18k▼
2024 · €21k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€2.56M€2.56M▲
Fixed assets21/28€2.55M€2.55M=
Financial fixed assets28€2.55M€2.55M=
Current assets29/58€7k€11k▲
Amounts receivable within one year40/41€302€7k▲
Other amounts receivable41€302€7k▲
Cash at bank and in hand54/58€4k€4k▼
Deferred charges and accrued income490/1€2k-
Equity and liabilities
Total equity and liabilities10/49€2.56M€2.56M▲
Equity10/15€754k€1.06M▲
Contributions10/11€5k€5k=
Profit (loss) carried forward14€749k€1.05M▲
Amounts payable17/49€1.81M€1.51M▼
Amounts payable after more than one year17€1.22M€1.12M▼
Financial debts170/4€1.22M€1.12M▼
Amounts payable within one year42/48€588k€389k▼
Current portion of amounts payable after more than one year42€101k€103k▲
Trade debts44€4k€4k▼
Suppliers440/4€4k€4k▼
Taxes, remuneration and social security45€31k€31k▲
Taxes450/3€31k€31k▲
Other amounts payable47/48€451k€251k▼
Income statement
Code20242025
Other operating charges640/8€89€695▲
Gross operating margin9900€101k€104k▲
Operating profit (loss)9901€101k€103k▲
Financial income75/76B€0€318k▲
Recurring financial income75€0€318k▲
Financial charges65/66B€24k€20k▼
Recurring financial charges65€24k€20k▼
Profit (loss) for the period before taxes9903€77k€402k▲
Income taxes67/77€21k€18k▼
Profit (loss) for the period9904€56k€383k▲
Profit (loss) for the period to be appropriated9905€56k€383k▲
Appropriation of the result
Profit (loss) to be appropriated9906€749k€1.13M▲
Profit (loss) brought forward from the previous period14P€692k€749k▲
Profit to be distributed694/7-€78k
Return on contributions (dividend)694-€78k
The notes to these accounts (3 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
09-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Equity above €1MEq €1.06M ▲40.5%
4 profitable years in a row build equity to €1.06M.
28-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 28 days late
2024
31-12
Financial
Weakest financial yearnet €56k ▼20%
Net result drops to €56k, the lowest in the series; recovery starts the following year.
10-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
03-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Watermaal-Bosvoorde · 1 establishment unit since 2021
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Elandstraat 581170 Watermaal-BosvoordeGround area
216 m²
Building footprint
140 m²
Volume, LiDAR
1,113 m³
Parcel 21017D0092/00S000, Brussels · tallest building 12.9 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
PharmaléaH
since 20212.326.911.521
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21017D0092/00S000 | Brussels | 216 m² | 1 · 140 m² | 12.9 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
PHARMACIE DU BATY
BE 0464.919.515
Profondeville · Eq €1.06M
APOTHEEK DE BRABANDERE
BE 0445.609.981
Schaarbeek · Eq €1.06M
PHARMACIES ENGELS
BE 0821.492.208
Malmedy · Eq €1.06M
PHARMACOZ
BE 0425.551.173
Gerpinnes · Eq €1.05M
PHARMACIE MATHIEU
BE 0882.228.955
Sivry-Rance · Eq €1.05M
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 2,965 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded25-11-2021
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.